In April 2014, when the federal government released physician-level Medicare payment data for the first time in decades, reporters sorting the spreadsheet found an ophthalmologist in North Palm Beach, Florida, sitting at the top of it. In a single year, 2012, Medicare had paid Dr. Salomon Melgen roughly twenty-one million dollars — more than any other physician in the United States. The figure was startling on its own. It became a national story because of a second fact the reporters already knew: the highest-billed doctor in America was also the co-star of a federal corruption investigation involving his close friend and frequent guest, the senior United States senator from New Jersey, Robert Menendez — a friendship of private jets, Dominican villas, and, prosecutors would allege, official favors that reached into the upper floors of the Department of Health and Human Services precisely when Medicare came asking for its money back.
Three years later, a jury in West Palm Beach convicted Melgen on all sixty-seven counts of health care fraud the government charged. The trial evidence described not aggressive billing but a practice built on manufactured disease: elderly patients diagnosed with a blinding condition many did not have, subjected to injections and laser burns they did not need, their charts decorated with boilerplate findings and, in some instances, test images belonging to other people’s eyes. Prosecutors put the fraud as high as one hundred million dollars. In February 2018, a federal judge sentenced the doctor, then sixty-three, to seventeen years. He served three. On his final night in office, President Donald Trump commuted the sentence, and Salomon Melgen went home to Palm Beach — unrepentant, insisting to the end that he had treated every patient in good faith. The case remains the fullest American parable of what fee-for-service medicine, political friendship, and executive clemency can do when they find one another.
The Practice
Melgen’s biography was the kind America advertises. Born in the Dominican Republic, trained in the United States, he built a chain of retina clinics across Palm Beach, St. Lucie, and surrounding counties — a specialist’s specialist in the diseases of the aging eye, in a state stocked with aging eyes. His signature diagnosis was wet age-related macular degeneration, a genuinely devastating condition in which abnormal blood vessels leak beneath the retina; untreated, it destroys central vision. Its treatment in the 2000s was transformed by injectable drugs, chief among them Lucentis, which at roughly two thousand dollars a dose became one of Medicare Part B’s largest single line items — and, because physicians buy the drug and bill the program at a markup, a revenue engine for retina practices. The economics mattered at trial. Lucentis was shipped in single-use vials containing modestly more drug than one dose. Melgen’s clinics harvested the overfill, treating three and sometimes four patients from one vial — and billed Medicare for a full vial each time, collecting several times over on drug he had bought once. Medicare flagged the pattern and demanded nearly nine million dollars back. Melgen fought the recoupment with lobbying as much as law — which is where the senator enters.
But the multi-dosing, ethically corrosive as the double billing was, formed the smaller part of the indictment. The core allegation was that the diagnosis itself was for sale. Government experts who reviewed patient files testified that large fractions of Melgen’s wet-AMD patients showed no sign of the disease; that his charts recorded findings the imaging contradicted; that he performed retinal laser treatments — on some patients, dozens of sessions — that the standard of care had abandoned; and that his practice performed and billed diagnostic tests at a volume without parallel in the specialty, including tests on prosthetic eyes. Patients testified about painful injections and burns, about vision that worsened under treatment, about trusting a confident man in a white coat because that is what patients do. The defense answered that Melgen was an aggressive clinician on the frontier of practice, that medicine tolerates outliers, and that the government was criminalizing judgment. Juries are usually receptive to that argument, which is why health-care-fraud trials against treating physicians are rare and risky. This jury deliberated and convicted on every count.
The Senator
The friendship between Melgen and Menendez was, by both men’s account, genuine — two Hispanic-American strivers of the same generation, godfathers to each other’s ambitions. It was also, the Justice Department alleged, a marketplace. Menendez flew repeatedly on Melgen’s private jet to the doctor’s villa in the Dominican resort of Casa de Campo, vacations he failed for years to disclose or reimburse; Melgen and his family channeled hundreds of thousands of dollars to committees supporting the senator. In return, prosecutors said, Menendez’s office pressed the State Department on visas for the married doctor’s foreign girlfriends; pushed executive agencies to protect Melgen’s interest in a Dominican port-screening contract; and — most consequentially — intervened up the chain of Medicare’s parent department as Melgen contested the multi-dosing recoupment, culminating in a 2012 meeting in which the senator pressed the secretary of Health and Human Services herself on the billing policy. The 2015 bribery indictment against both men survived years of legal challenge, went to trial in Newark in the fall of 2017, and died in a hung jury that November. After the Supreme Court’s narrowing of official-act bribery in the McDonnell case, the department dropped the prosecution in early 2018; a judge had already acquitted the defendants on several counts. Menendez returned to the Senate, survived an admonition from the Ethics Committee, and won re-election — his later, unrelated gold-bars conviction in New York belongs to another chapter. Melgen, by contrast, had no Senate seat to return to. Two months after the Newark collapse, the Florida jury’s verdict caught up with him at sentencing.
Seventeen Years, Three Served
At the February 2018 sentencing, prosecutors sought thirty years, describing a man who had “stole[n] from Medicare” on a historic scale and physically harmed the elderly patients whose trust financed it. The defense produced patients who swore he had saved their sight, and colleagues attesting to charity work in Florida and the Dominican Republic. Judge Kenneth Marra imposed seventeen years and ordered restitution in the tens of millions — a figure litigated afterward, with the government’s loss calculations reaching well past forty million dollars. Melgen surrendered his medical license and his appeal failed. He was sixty-six, diabetic, and housed in a federal medical facility when the pandemic arrived, and his petition for compassionate release was pending in the ordinary channels when the extraordinary channel opened instead. On January 19, 2021, in the final clemency batch of his first term, President Trump commuted the sentence in full. The White House statement cited Melgen’s age, health, charitable works — and letters of support, prominently including advocacy from friends and family and, as widely reported, from Senator Menendez. The restitution obligations survived; the imprisonment did not. Of the seventeen years a jury’s verdict had produced, Salomon Melgen served roughly three.
The Spreadsheet War
The data release that exposed Melgen was itself the end of a thirty-five-year legal war, and the history explains why he could bill at that scale for so long in the dark. In 1979, a federal court in Florida — at the urging of the Florida Medical Association and the American Medical Association — enjoined the government from disclosing what Medicare paid individual physicians, reasoning that doctors’ privacy outweighed the public’s interest in the ledger. The injunction held for a generation, surviving journalism’s repeated assaults, until Dow Jones, the Wall Street Journal’s parent, persuaded a federal judge to vacate it in 2013. When the Centers for Medicare and Medicaid Services published the 2012 payment file the following April, the top of the distribution told the whole story of unwatched fee-for-service medicine: a tiny cohort of physicians collecting sums that dwarfed entire group practices, with ophthalmology — carried by the two-thousand-dollar injectable Lucentis — dominating the extreme tail. Melgen’s twenty-one million dollars sat above them all. Journalists needed a spreadsheet sort to find him; the program’s own integrity contractors had needed a decade and had managed only a contested recoupment demand that a senator’s office was actively working to smother. The episode became Exhibit A for transparency advocates, and the annual release of physician payment data — now routine — is, in a real sense, Melgen’s monument.
The Vial Rule
The numbers at sentencing deserve their own paragraph, because they measure the distance between what a jury can prove and what a program lost. Judge Marra found that Melgen’s intended fraud exceeded seventy million dollars and that Medicare’s actual loss was forty-two million; he ordered restitution of $42.6 million, with the government free to seek more. The figures made Melgen, by the Justice Department’s accounting, one of the largest individual physician frauds in the program’s history — and they rested, at bottom, on a vial.
The overfill loophole itself outlived him only briefly. Beginning in 2017, Medicare required physicians to bill discarded drug under a dedicated claim modifier — the “JW” code — making the gap between drug purchased and drug administered visible in the claims data for the first time; a companion modifier later required doctors to attest affirmatively when nothing was discarded. Then, in the 2021 infrastructure law, Congress went to the source: manufacturers of single-use vials must now refund Medicare for discarded drug beyond a modest allowance, a provision that took effect in 2023 and converted the overfill from a physician’s temptation into a manufacturer’s liability. It is a pattern American health policy repeats endlessly: the loophole is closed not when the doctor exploits it but when the exploitation becomes arithmetic someone is finally forced to see. Melgen multi-dosed for years in a claims system that could not distinguish one vial from three. The system can now. That reform, like the data release, is part of his ledger.
The Anatomy of the Trial
The 2017 trial in West Palm Beach ran nearly two months, and its texture rewards attention because it shows how a jury is persuaded to do the thing juries most resist: convict a treating physician for his treatment. The government did not rest on statistics. It walked jurors through individual charts — patients diagnosed with wet macular degeneration whose scans showed dry or no disease; eyes subjected to scores of laser sessions after the specialty had largely abandoned the therapy for that indication; diagnostic tests billed on eyes that could not see because they were prosthetic. Government experts testified that when they reviewed samples of his files, the disease he billed for was absent in a large share of them. The defense called patients who credited Melgen with their sight and experts who cast him as a clinical maverick; the jury heard, too, about the practice’s volume — exam rooms cycling like an airline hub, tests ordered by protocol before any physician looked. The unanimous sixty-seven-count verdict rejected the maverick theory in the only vocabulary courts recognize. And it landed on a man already twice defined in courtrooms: the Newark bribery jury had hung five months earlier, and the two prosecutions together framed the question his career now permanently poses — whether the billing machine funded the friendship or the friendship protected the machine. The evidence at both trials suggested the honest answer was: each, in turn.
The Senator’s Sequel
There is a coda, and it belongs to the friend. Robert Menendez survived the Melgen affair intact — the hung jury, the dropped charges, the Ethics Committee’s letter of admonition, re-election. In 2023, federal prosecutors in Manhattan indicted him again, on facts so lurid they retired the Melgen case as the defining scandal of his career: gold bars and envelopes of cash found in his home, a Mercedes convertible, allegations that the chairman of the Senate Foreign Relations Committee had acted as an agent of Egypt. In July 2024 a jury convicted him on every count. He resigned his seat that August; in January 2025 a federal judge sentenced him to eleven years; and on June 17, 2025, he reported to a federal prison in Pennsylvania — the first senator in American history imprisoned for acting as a foreign agent.
The symmetry is almost too exact. The senator whose advocacy once reached the secretary of Health and Human Services on behalf of a friend’s billing dispute will serve, if his sentence stands, nearly four times as long as that friend actually served for sixty-seven felonies. The difference was not the gravity of the conduct. It was the clemency — the one variable in the system that answers to no chart review, no guideline, and no appeal. Melgen drew a president’s attention; Menendez, so far, has not. In the economy of American accountability, that distinction can be worth fourteen years.
Neither man, it bears recording, has ever conceded anything. Melgen emerged from prison insisting he had treated every patient in good faith and had been persecuted for practicing aggressive medicine; Menendez walked into his own sentencing proclaiming himself a scapegoat and his prosecution political. The two friends’ parallel certitude is its own datum. Between them, three federal juries heard the evidence — one hung, two convicted on every count presented — and the men those juries judged remain, in their own accounts, the only honest actors in the story. Systems can be audited. Self-regard cannot.
The Arithmetic of Trust
It is tempting to read the Melgen case as an outlier — the greediest doctor in the richest program in the most Medicare-dense corner of America. The uncomfortable reading is structural. Fee-for-service medicine pays for units of treatment, not units of truth; every safeguard between the two is a professional’s conscience backstopped by an auditor’s algorithm. Melgen was not hard to see. He was, literally, the first row of the spreadsheet — an outlier so extreme that his billing exceeded entire hospital systems’ — and the program paid him for years while its contractors processed his appeals. The 2014 data release that exposed him happened over the organized objection of physician groups that had kept payment data sealed for three decades. Transparency, when it finally arrived, did in one news cycle what utilization review had not done in ten years. That is a lesson about sunlight, and an indictment of everyone who preferred the shade.
The clemency completes the parable. The pardon power is absolute and its exercise here was lawful; that is precisely what makes it instructive. A physician convicted by a unanimous jury of sixty-seven felonies against the public health program — whose victims were his own patients — recovered his liberty not through the courts, which had rejected him at every level, but through access: the accumulated capital of friendship, donation, and advocacy reaching the one official whom no standard binds. Every doctor who ever hesitated over an upcoded claim, every compliance officer who ever preached that the system catches cheaters, absorbed the counter-lesson at once. The system caught him. The system convicted him. And the system’s summit let him out, for reasons no regulation will ever audit. The elderly patients whose retinas bore the treatment marks got no such review. Their case was closed the day the jet left for Palm Beach.